Meeting
2011 ASCO Annual Meeting
Redefining CTCs: Detection of additional circulating tumor cells using an antibody capture cocktail and HER2 FISH.
Authors
F. Z. Bischoff
Biocept Inc., San Diego, CA
F. Z. Bischoff , T. J. Pircher , T. Pham , K. Wong , S. Mikolajczyk , P. Cotter , J. A. Mayer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Staging
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10631)
Abstract #
10631
Poster Bd #
35H
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
![Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology [CEE]).](https://d201v5jt9ylckg.cloudfront.net/102/6661/59677/59677_poster_pv.jpg)
Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology [CEE]).
First Author: S. Krishnamurthy
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The expanded indications of HER2-targeted therapies by monitoring of circulating tumor cells.
First Author: Yasuaki Kimura
Poster
2022 ASCO Annual Meeting
CK+/CD45+ (dual-positive) circulating cells are associated with prognosis in patients with advanced breast cancer.
First Author: Carolina Reduzzi
Poster
2020 ASCO Virtual Scientific Program
Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.
First Author: Erika Paige Hamilton